News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI
dana-farber.org
Nov 26, 2024, 17:58

Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI

Dana-Farber’s Breast Oncology Center shared a post on X:

“We are leading a phase 2 study, called TRUDI, to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn if the intervention works in stage III, HER2-expressing Inflammatory Breast Cancer.”

Dana-Farber’s Breast Oncology Center is leading a phase 2 study called TRUDI

Read further.

More featuring Dana-Farber’s Breast Oncology Center.

cancer Dana-Farber’s Breast Oncology Center Durvalumab inflammatory breast cancer OncoDaily Oncology Trastuzumab deruxtecan TRUDI
Special Coverage
Blog
Jan 6, 2025, 16:49
Tackling Disparities in Childhood Cancer Outcomes: The IGNITE Consortium's Mission
Science
Jan 6, 2025, 16:37
Priyamvada Maitre: 2025 begins with IJROBP - The Red Journal
Science
Jan 6, 2025, 16:35
Francisco Conesa Buendia: Advancing CAR-T Therapy for Solid Tumors - Breaking Barriers with Innovation
Career
Jan 6, 2025, 16:35
Sophia Ononye started a new position as Adjunct Professor at Concordia University Irvine
Science
Jan 6, 2025, 16:30
Rahul Banerjee: A good reminder by Danai Dima that talquetamab can be used before BCMA CAR-T
Blog
Jan 6, 2025, 16:00
Lazar Popovic: Inviting you to the 14th Novi Sad Oncology Congress
Blog
Jan 6, 2025, 15:59
Nelson Dusetti: Thrilled to visit IRCCS Ospedale San Raffaele
Blog
Jan 6, 2025, 15:56
Aman Chauhan: I had a fantastic time working with AJCC on the Latest NET staging
Insight
Jan 6, 2025, 15:49
Talha Badar: DDX41mt predisposition syndrome in myeloid neoplasms
Science
Jan 6, 2025, 15:47
Moazzam Shahzad: Exploring allo-HCT outcomes in geriatric patients
Science
Jan 6, 2025, 15:06
Ali Nabavizadeh: The link between radiomics and immunological traits in pediatric low-grade glioma
Science
Jan 6, 2025, 15:04
Patrick Hwu: How can we make cancer vaccines more effective?